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Introduction
Frontotemporal dementia (FTD) and motor neuron disease (MND), with amyotrophic lateral sclerosis (ALS) as the most frequent form, are closely related clinical syndromes with overlapping molecular pathogenesis. Abnormal intracellular accumulation of the transactive response DNAbinding protein with molecular weight 43 kD (TDP-43) is a characteristic neuropathological feature of the most common molecular subtype of FTD (frontotemporal lobar degeneration with TDP-43 pathology, FTLD-TDP) and the majority of ALS cases [10, 21, 29] . Recently, abnormal expansion of a GGGGCC hexanucleotide repeat in a non-coding region of the chromosome 9 open reading frame 72 gene (C9ORF72) was discovered to be the most common genetic abnormality in familial and sporadic FTD and MND, and the cause in most families where both, FTD and MND, are inherited in an autosomal dominant fashion [14, 17, 31] . The number of hexanucleotide repeats in the normal population ranges from 2 to 24 [13, 14, 17, 31, 39] , whereas up to several thousand repeats (range 700-4,400 repeats) are described in the pathologically expanded allele as estimated by Southern blot analysis [5, 13, 14] . The mechanism by which the mutation leads to neurodegeneration is uncertain; however, initial reports provided evidence for both loss-of-function and toxic-gainof-function mechanisms, by demonstrating a reduction in C9ORF72 mRNA levels and the presence of potentially toxic RNA foci, respectively [14, 17] .
The neuropathology of cases carrying the C9ORF72 mutation and of cases previously described as linked to chromosome 9 has consistently been reported to be characterized by TDP-43 immunoreactive inclusions in neurons and glia [7, 10, 12, 14, 17, 19, 23, 26, [33] [34] [35] 38] . Cases with clinical FTD are found to have FTLD-TDP which most often fits the type B pattern, although some cases have additional features of type A [19, 22, 26] . Cases with the mutation and clinical ALS show TDP-43 pathology indistinguishable from classical sporadic ALS, with TDP-43 inclusions in both upper and lower motor neurons [12, 35, 38] . The extent of pathological overlap among cases is even greater than the overlap in clinical features, with almost all C9ORF72 mutation cases having at least some TDP-43 pathology in both the frontotemporal cortex and the pyramidal motor system, as well as a wide range of other neuroanatomical regions [19, 35] .
In addition to TDP-43 pathology, a unique and consistent feature of cases with the C9ORF72 mutation is the presence of inclusions that are immunoreactive for markers of the ubiquitin proteasome system (UPS; including ubiquitin, ubiquilins and p62), but negative for TDP-43, particularly in the cerebellar cortex, hippocampus and cerebral neocortex [1, 8, 12, 19, 23, 35, 38] . Recently, two independent studies demonstrated that this UPS-positive, TDP-43-negative pathology is the result of unconventional translation of the abnormally expanded GGGGCC repeat region [4, 24] . Translation of the sense transcript in the three alternate reading frames generates three different polypeptides, each composed of repeating units of two amino acids (dipeptide repeats, DPRs): glycine-alanine (GA), glycine-proline (GP) or glycine-arginine (GR). In each study, antibodies generated against these DPR proteins were shown to label TDP-43-negative inclusions in cases with the C9ORF72 mutation, but not in any control samples. A similar process of repeatassociated non-ATG-initiated translation has been reported in other non-coding repeat expansion disorders, including spinocerebellar ataxia type 8, myotonic dystrophy type 1 and fragile X tremor ataxia syndrome, in disease-relevant tissues [11, 25, 36, 41] , suggesting DPR production as another possible pathogenic mechanism of C9ORF72 mutations.
In the present study, we generated novel monoclonal antibodies against poly-GA with the aim of characterizing the neuroanatomical distribution and clinico-pathological association of DPR pathology in a large cohort of cases with the C9ORF72 mutation that included a broad spectrum of clinical phenotypes.
Materials and methods

Generation of monoclonal anti-GA antibody
Since our previous study showed the most abundant staining of DPR pathology with a polyclonal antiserum against poly-GA [24], we decided to generate monoclonal antibodies against poly-GA for this study. 30 μg of insoluble recombinant peptide with ten GA repeats linked to polyethylene glycol (C-PEG-GA 10 ) were used to immunize CBL mice subcutaneously and intraperitoneally with a mixture of 5 nmol CpG 2006 oligonucleotide (Tib Molbiol, Berlin, Germany), 150 μl PBS and 150 μl incomplete Freund's adjuvant. After a 6-week interval, mice were boosted with 30 μg peptide in PBS. Hyperimmune spleen cells were fused with the mouse myeloma cell line P3X63Ag8.653 using standard procedures. The supernatants were first screened in an enzyme-linked immunosorbent assay (ELISA) and selected supernatants tested by immunoblot and immunohistochemistry. The clone 5E9 of subclass IgG1 and clone 5F2 of subclass IgG2a were stably subcloned and used for further characterization.
Immunoblot
The specificity of mAb 5E9 and 5F2 was tested by SDS-PAGE and immunoblot. 250 ng of recombinant GST-GA 15 , GST-GP 15 , GST-GR 15, GST-AP 15 and GST-PR 15 proteins, generated as described [24] , were separated by 12 % SDSpolyacrylamid gel electrophoresis and transferred onto polyvinylidene difluoride membranes (Millipore, Billerica, MA). Following transfer, membranes were blocked with 0.2 % I-Block (Applied Biosystems) in TBS with 0.2 % Triton X-100 for 1 h, incubated with primary monoclonal antibody 5E9 and 5F2 (dilution 1:50) overnight at 4 °C. Antibody binding was detected with horseradish peroxidase (HRP)-conjugated anti-mouse IgG (Promega) and signals were visualized by an HRP-based chemiluminescent reaction using the ECL reagents (GE healthcare) and exposed to X-ray films (SuperRX, Fujifilm).
Cases
35 cases with a C9ORF72 mutation from the brain banks affiliated with the University of British Columbia, University of Munich, University of Tuebingen and University of Amsterdam were included in the study. Consent for autopsy was obtained from the legal representative in accordance with local institutional review boards.
Some of the cases had previously been included in the original study that identified C9ORF72 as the disease gene [14] , while the other cases were identified by routine genetic testing for C9ORF72 repeat expansion of FTD and ALS cases in the respective brain banks using repeatprimed PCR as described [14, 31] . Clinical records from all cases were reviewed for age at onset, disease duration, family history, features of dementia, signs of MND and other neurologic-psychiatric symptoms.
Neurological control cases used to investigate specificity of anti-GA immunohistochemistry included FTLD-TDP with GRN mutations (n = 2), sporadic FTLD-TDP (n = 2), sporadic ALS-TDP (n = 4), FTLD-tau (n = 2), Alzheimer's disease (n = 2), Lewy body disease (n = 2), FTLD-FUS (n = 2) and normal control tissue from elderly patients with no history of neurological disease (n = 2).
Histology and immunohistochemistry
Histological examination was performed on 5-8 μm thick sections cut from formalin-fixed, paraffin-embedded tissue of nine different CNS regions from C9ORF72 mutation cases when available: primary motor cortex, frontal cortex, occipital cortex, striatum, hippocampus, midbrain, medulla, cerebellum and spinal cord. Sections were stained with hematoxylin and eosin, and Luxol fast blue-periodic acidSchiff, or used for immunohistochemistry.
In addition to the anti-poly-GA mAbs 5E9 and 5F2 used to demonstrate DPR pathology (tested dilution range for both 1:5-1:2,000), other antibodies used in this study included rabbit polyclonal anti-TDP-43 (ProteinTech Group; dilution 1:2,000), rat monoclonal anti-pTDP-43 clone 1D3 (own production [28] , dilution 1:1,000), polyclonal rabbit anti-ubiquitin (DAKO, dilution 1:500) and mouse monoclonal anti-p62 (lck ligand, BD Biosciences, dilution 1:500).
Immunohistochemistry was performed using the Ventana BenchMark XT automated staining system (Ventana, Tuscon, AZ) with the AEC detection kit or iVIEW DAB detection kit, or the Leica BOND-MAX automated staining system (Leica) with Novocastra Bond Polymer Refine Detection Kit. For all antibodies heat-induced antigen retrieval with citrate buffer pH 6 was performed.
To ensure consistency of anti-poly-GA staining among different staining systems used at the three participating centers (Vancouver, Tubingen, Munich), selected sections were stained with different protocols showing comparable immunoreactivity. All sections and cases were stained with mAb 5E9, anti-p62 and anti-TDP-43. Selected cases were also stained with the mAb 5F2 which showed similar results to those with mAb 5E9. [32] .
Semiquantitative evaluation of pathology
The number of DPR, TDP-43 and p62-immunoreactive inclusions was scored in the different anatomical regions using a semiquantitative grading system, in which the overall number of immunoreactive inclusions (total score) as well as the number of neuronal cytoplasmic inclusions (NCI), neuronal intranuclear inclusions (NII) and dystrophic neurites (DN) were each rated as being absent (0), rare (1), occasional (2), moderate (3) or numerous (4). Inclusions were considered ''rare'' if only a few examples could be found in the entire region examined, ''occasional'' if they were relatively easy to find, but not present in every medium power microscopic field, ''moderate'' if at least a few examples were present in most microscopic fields and ''numerous'' when many were present in every microscopic field.
Degeneration of brain regions was assessed on H&E and myelin-stained (corticospinal tract) sections and graded as absent (0), mild (1), moderate (2) or severe (3) based on the presence of spongiosis, neuronal loss, gliosis or demyelination in the cortical, subcortical, brainstem or spinal cord regions. Cerebellum sections were screened for cell loss in the granular cell layer, Purkinje cell loss and thinning of the molecular layer.
Statistics
Statistical analysis was performed with the GraphPad Prism software (version 5.0). Group comparison for age at onset and disease duration was analyzed by one-way analysis of variance (ANOVA) with Newman-Keuls post hoc test. Nonparametric Kruskal-Wallis (ANOVA) followed by Dunn's post hoc test or Mann-Whitney U test was used to assess differences in degeneration levels and inclusion scores among clinical groups for each anatomical region. Significance level was set at p < 0.05 (two sided).
Correlation analysis was examined for age at onset, disease duration and levels of neurodegeneration with DPR and TDP-43 pathology in distinct brain regions using Spearman's rank correlation coefficient, with p values <0.01 adjusted for multiple comparisons considered as significant.
Results
Characterization of novel anti-GA monoclonal antibodies
Monoclonal antibodies were generated against aggregated synthetic peptide with ten GA repeats. Hybridoma supernatants were pre-screened by ELISA and positive supernatants were tested by immunoblot. mAb 5E9 and 5F2 showed a selective and sensitive detection of recombinant GST-GA in immunoblot (Fig. 1a) and was used for further analysis.
Next, mAb 5E9 and 5F2 were tested by immunohistochemical analysis on cerebellum of selected cases to determine their applicability and sensitivity in this assay. Both antibodies robustly and specifically labeled pathologic inclusions in paraffin-embedded tissue of C9ORF72 case including NCI, NII and DN (Fig. 1b) using a wide dilution range from 1:5 to 1:500 with heat antigen retrieval being found to significantly enhance immunoreactivity. In contrast, no labeling was observed in the cerebellum of ALS-TDP and FTLD-TDP cases without a C9ORF72 mutation (Fig. 1b) or in the characteristic pathological lesions of other neurodegenerative diseases such as Lewy bodies, neurofibrillary tangles and senile plaques (data not shown).
Double-labeling immunofluorescence of cerebellum and hippocampus of selected cases revealed a complete colocalization of poly-GA immunoreactivity with p62-positive inclusions (Fig. 1c, d) . Furthermore, some NCI and DN were only labeled for poly-GA (Fig. 1c) . Together, these data demonstrate the high sensitivity and specificity of the novel mAb 5E9 and 5F2 to detect C9ORF72 mutation-associated poly-GA DPR pathology.
Study cohort
A total of 35 cases with a C9ORF72 mutation were included in the study to investigate the neuroanatomical distribution pattern of DPR pathology in detail. Demographics and clinical features of the cases are summarized in Table 1 . According to the available clinical information, cases were grouped into those with a pure/predominant MND phenotype (MND group, n = 8), pure/predominant FTD phenotype (FTD group, n = 9) and mixed FTD/MND (FTD/MND group, n = 18). Significant differences were identified among the groups for disease onset (later onset in the MND group than in the FTD/MND and FTD group, p = 0.0262, ANOVA, p < 0.05, Newman-Keuls post hoc test) and for disease duration (longer disease duration in the FTD group than in the FTD/MND and MND groups; p = 0.0165, ANOVA, p < 0.05, Newman-Keuls post hoc test).
Spectrum and distribution of DPR pathology in C9ORF72 cases
Multiple CNS regions were analyzed for DPR pathology by immunohistochemistry with the mAb 5E9 and the presence and frequency of poly-GA-immunoreactive lesions (total amount as well as individual scores for NCI, NII and DN) was assessed semiquantitatively for each region (Table 2) .
Overall, mAb 5E9 staining was found to be robust and intense in all cases with no obvious influence of postmortem delay or duration of formalin fixation. A remarkably homogenous distribution pattern and amount of DPR pathology was observed in all C9ORF72 mutation cases in the neocortical regions examined (including frontal, motor and occipital cortex), with moderate to numerous 1 3 NCI in layers II-VI (Fig. 2a, b) . The morphology of NCI varied from granular dot like in small non-pyramidal neurons to ring and star-like inclusions in pyramidal neurons (Fig. 2c, d ). Sometimes, neurons with diffuse cytoplasmic anti-GA staining ("pre-inclusions") were observed (Fig. 2e) . Interstitial white matter neurons were often found to contain NCI, while no inclusions in glial cells or axonal processes were seen in the white matter. NII and DN were a consistent, but more variable finding. NII could be found in cells with and without NCI. DN were usually small and delicate ( Fig. 2c ) and large swollen neurites were rare.
In the hippocampus, moderate to numerous NCI and NII were detected in all cases in the dentate granule cells (Fig. 2f ) and in the pyramidal layer, primarily in the CA3/4 region ( Fig. 2g, h ). NCI in CA pyramidal neurons had a mainly star-like or ring-like appearance.
All C9ORF72 cases showed abundant DPR pathology in the cerebellum. In addition to small granular, dot-like NCI and NII in the granule cells (Figs. 1b, 2j ), NCI and NII were consistently found in the molecular layer (Fig. 2i) and occasionally NCI were identified in Purkinje cells (Fig. 2j) . A subset of cases revealed rare "pre-inclusions" with diffuse labeling of Purkinje cells (Fig. 2k) and neurons in the molecular layer. Neuritic pathology in the cerebellum was most abundant and consistent in the molecular layer ( Fig. 2i ) and more variable in the granular layer. DPR pathology ranging from absent to abundant was observed in the striatum (Fig. 2l ) and in the pigmented neurons of the substantia nigra pars compacta (Fig. 2m) .
DPR pathology was absent or sparse in the hypoglossal motor nuclei and the anterior horn of the spinal cord, with a small number of cases in each clinical group showing single NCI (Fig. 2n) . In addition, single NCI in the posterior horn of the spinal cord and in the cuneate nuclei were detected.
Many of the small dot-like cytoplasmic inclusions in the cortical areas were observed in cells with small nuclei, which could either be small neurons or glial cells. To further address this, we performed double-label immunofluorescence for poly-GA and cell-specific markers. Cytoplasmic and nuclear poly-GA inclusions were found in cells colabeled with the neuronal marker NeuN, but there were no poly-GA positive inclusions in cells that were labeled with the astrocyte marker GFAP, the microglial marker Iba1 or CNPase as oligodendroglial marker (Supplementary Fig. 1 ).
Relation of DPR and TDP-43 pathology
To investigate the relationship between DPR and TDP inclusion body formation, we assessed TDP-43 pathology in each of the examined regions (Table 3 ). All cases with sufficient cortical pathology were classified as FTLD-TDP type B pathology (n = 30), characterized by compact or diffuse granular NCI and some DN in superficial and deep cortical layers. A subset of cases (n = 8) had additional features of FTLD-TDP type A with compact oval or crescentic NCI with abundant short DN, predominantly localized to layer II and one had additional pathological features of type C with many long DN. Double-label immunofluorescence for TDP-43 and poly-GA was performed in selected cases. Neurons in neocortical regions were often found to contain either TDP-43 or poly-GA inclusions (Fig. 3a) . Notably, vulnerable neurons like Betz cells in cases with MND were found to contain TDP-43 pathology, whereas DPR pathology was usually seen in small neurons (Fig. 3b) . However, in the hippocampal dentate granule cells in cases with high TDP-43 load in this region, accumulation of both proteins in individual neurons was observed with poly-GA aggregates present in the center being surrounded by accumulated TDP-43 (Fig. 3c-e) . No association between cytoplasmic TDP-43 accumulation and presence/absence of poly-GA NII pathology was observed and no poly-GA immunoreactivity was observed with oligodendroglial TDP-43 inclusions in the white matter.
Clinico-pathological correlations
To gain further insights into the pathomechanisms of the C9ORF72 mutation, we performed detailed statistical analysis to investigate the correlations among clinical phenotypes, regional neurodegeneration, DPR pathology and TDP-43 pathology.
First, we investigated group differences in the amount and anatomic distribution of pathologies among the three clinical groups. As shown in Table 2 and illustrated in the lesion profiles (Fig. 4) , different patterns of neurodegeneration were present among the three clinical groups, as expected. Cases with clinically pure MND had significantly less degeneration in the frontal cortex compared to the FTD/MND (p < 0.05, Dunn's post hoc test) and FTD groups (p < 0.001, Dunn's post hoc test). In contrast, cases with clinically pure FTD had less degeneration in the anterior horn of the spinal cord compared to MND (p < 0.01, Dunn's post hoc test) and FTD/MND cases (p < 0.05, Dunn's post hoc test) and less degeneration of (Table 3 ; Fig. 4 ). For DPR pathology, a strikingly similar pattern was observed among all cases with high scores in all neocortical regions, cerebellum and hippocampus, moderate numbers in the striatum and midbrain and low scores in the medulla and spinal cord ( Table 2 ; Fig. 4) . As a result, there were no significant differences among the three clinical groups in the amount of DPR pathology in any of the brain regions examined (p > 0.05, Kruskal-Wallis ANOVA). Notably, the highest levels of DPR pathology in the striatum and substantia nigra were observed in cases with additional clinical features of parkinsonism. A trend for higher levels of DPR pathology in these regions was observed among cases with extrapyramidal syndromes (Table 1 , n = 8 with brain regions available); however, it did not reach statistical significance (p = 0.2371 substantia nigra, p = 0.2365 striatum, Mann-Whitney U test).
We further investigated the relationship between the amount of DPR and TDP-43 pathology with the grade of neurodegeneration (Spearman's rank correlation coefficient, Table 4 ). There were strong positive correlations between the degree of degeneration and TDP-43 pathology in the frontal cortex (ρ = 0.62, p < 0.0001), primary motor cortex (ρ = 0.70, p < 0.001), spinal cord (ρ = 0.74, p < 0.0001) and hypoglossal nucleus (ρ = 0.75, p < 0.0001) and a moderate positive correlation in the substantia nigra (ρ = 0.58, p < 0.001). Moreover, a strong negative association was No significant correlations were identified between the severity of DPR pathology and the degree of neurodegeneration in any of the examined regions (Table 4) , the age at onset and disease duration.
Discussion
An abnormal hexanucleotide expansion in C9ORF72 is the most common genetic cause of MND and FTD. However, the mechanisms of how this intronic mutation contributes to neurodegeneration are unclear, with three pathogenic mechanisms proposed: loss of C9ORF72 function, toxic RNA gain of function and toxicity due to unconventional non-ATG translation products [6, 13, 30] . Here, we describe for the first time a detailed clinicopathological correlative study of DPR and TDP-43 pathology in 35 C9ORF72 mutation cases that provide new insights into the potential roles and links of DPR and TDP-43 aggregation in C9ORF72 pathogenesis.
The novel anti-GA antibodies 5E9 and 5F2 generated in this study were characterized as powerful tools for sensitive and specific detection of DPR pathology. This was demonstrated by the robust and highly specific labeling of inclusions in C9ORF72 mutation cases, the absent immunoreactivity in healthy and neurologic controls, in line with previous studies using polyclonal antibodies [4, 24] and the high sensitivity of these antibodies to detect the TDP-43-negative, UPS-positive pathology characteristic for C9ORF72 mutation cases [1, 8, 12, 19, 23, 35, 38] as demonstrated by double-labeling experiments showing complete co-localization with p62 immunoreactivity in selected anatomical regions, such as the cerebellum and CA3/4 region.
The demographics and clinical phenotypes of our studied cohort of 35 C9ORF72 cases were representative of the wide clinical spectrum previously associated with the C9ORF72 mutation [7, 9, 12, 15, 19, 23, 26, [33] [34] [35] 40] . About 50 % of our cases presented with features of mixed FTD and MND and about 25 % with predominant FTD or MND, respectively. Other clinical features that have been described in some patients with the C9ORF72 mutation, such as extrapyramidal symptoms [7, 12, 15, 19, 26, 33] and psychiatric features [2, 7, 15, 16, 19, 33, 34] , were also represented in our cohort.
The predominant types of DPR pathology were cytoplasmic and intranuclear inclusions restricted to neurons, as confirmed by double-labeling experiments with NeuN as a specific neuronal marker. No inclusions were detected in cells labeled with an astrocyte-specific marker, consistent with previous reports [4] and moreover inclusions were also not found in microglia and oligodendrocytes. The morphology, amount and anatomical distribution of DPR pathology were found to be strikingly homogenous among all cases with high numbers in the cerebellum, hippocampus and throughout the cerebral neocortex, more variable in the striatum and substantia nigra and rare or absent in the medulla and spinal cord, consistent with the distribution pattern described using anti-GP antibodies [4] .
Aggregation of proteins into characteristic lesions and inclusion bodies is a common theme in neurodegenerative diseases; however, the actual pathomechanistic function of inclusion bodies is a hot topic that has been debated in the field of neurodegenerative diseases for decades [20, 37] . Based on the observations that there is sometimes only poor correlation between the neuropathological hallmark lesions seen with neurodegeneration or phenotype, with the most prominent examples perhaps being the rather poor association of amyloid beta load with cognitive impairments [27] and intranuclear inclusions in Huntington's disease [18] , Tables 2 and 3 . Note the close correspondence in the patterns of TDP-43 pathology and neurodegeneration which vary according to the clinical phenotype (more frontal cortical involvement in cases with FTD and more hypoglossal nucleus and spinal cord involvement in cases with clinical MND). In contrast, DPR pathology shows the same pattern in all disease groups with no correlation with the pattern of degeneration. CE cerebellum, FCtx frontal cortex, MCtx primary motor cortex, OCtx occipital cortex, SC anterior horn of spinal cord, SN substantia nigra, STR anterior striatum, XII motor nucleus of hypoglossal nerve there is increasing evidence that insoluble aggregates per se might not be the primary neurotoxic agents and that soluble precursor species to mature aggregates might be the causative pathogenic species [3, 20, 37] . In line with this, inclusion body formation might instead serve as a protective function of the cell to dispose the neurotoxic species. Our data do not support a direct causative role for aggregated DPR proteins in neurotoxicity, as evidenced by the poor correlation between the anatomical distribution of DPR inclusion bodies and neurodegeneration (e.g., low DPR load in vulnerable motor neurons and high load in occipital cortex and cerebellum, regions usually not affected). However, our data are consistent with a model where soluble precursors to aggregated DPR proteins play a role in neurotoxicity, while the formation of visible DPR inclusion bodies is possibly protective. While studies such as this one using postmortem tissue from patients with end stage disease can provide important insights into potentially relevant disease mechanisms, the further elucidation of probably neurotoxic soluble DPR species can only be addressed by in vitro and in vivo experimental studies in C9ORF72 cell culture and animal models.
Another interpretation of our finding of a highly consistent distribution pattern of DPR pathology is that this might reflect the physiological pattern of C9ORF72 expression. In support of this, initial studies [14, 31] demonstrated RNA levels of C9ORF72 to be highest in cerebellum, a region heavily affected by DPR pathology. However, a detailed analysis of C9ORF72 expression including analysis of the relative expression of the various C9ORF72 transcripts, ideally at the cellular level, will be needed to further address this.
The other characteristic hallmark lesion in C9ORF72 mutation cases is TDP-43 accumulation [7, 10, 12, 14, 17, 19, 23, 26, [33] [34] [35] 38] with so far one notable exception of a Belgian FTD patient who carried the C9ORF72 mutation, but lacked detectable TDP-43 pathology [24] . All C9ORF72 mutation cases in our cohort of 35 cases showed TDP-43 immunoreactive inclusions in a range of neuroanatomical regions consistent with previous reports. There were significant differences among the clinical groups, with MND cases showing more TDP-43 pathology in lower motor neurons than cases with pure FTD (unfortunately, primary motor cortex was not available in FTD cases) and, patients with predominant FTD showing more TDP-43 pathology in the frontal cortex compared to the other groups. Together with the strong positive correlations between the amount of TDP-43 pathology and the degree of degeneration found in key anatomical regions such as frontal cortex, motor cortex and spinal cord, our data imply that alterations caused by the C9ORF72 mutation result in TDP-43 dysmetabolism and accumulation as a secondary downstream effect and that this likely plays a central role in the neurodegenerative process. The link between C9ORF72 mutation and TDP-43 is so far completely unknown. Although the presence of DPR and TDP-43 co-accumulation in the same neurons was a rare event, the composition of these combined inclusions with a central core consisting of DPR proteins being surrounded by TDP-43 suggests that DPR pathology precedes TDP-43 accumulation and might therefore trigger TDP-43 accumulation, at least in a subset of neurons. Future studies using cellular and animals models are needed to further elucidate the link between DPR and TDP-43 aggregation, as well as other effects of the C9ORF72 repeat expansion (such as reduced production of specific C9ORF72 isoforms, the formation of RNA foci and the GGGGCC repeat length) on TDP-43 metabolism. Moreover, the identification of additional C9ORF72 mutation cases with pure DPR pathology would provide important insights into the role and relevance of DPR and TDP-43 pathology in disease pathogenesis.
In summary, our data confirm the presence of DPR pathology as a highly specific and sensitive marker for the C9ORF72 repeat expansion mutation and extend the description of the morphology and anatomical distribution of DPR inclusions. Novel DPR antibodies such as ours will be powerful tools in the routine diagnosis of neurodegenerative diseases, in the evaluation of emerging C9ORF72 cellular and animal models to dissect the complex mechanisms of the C9ORF72 mutation and potential links between DPR proteins, RNA toxicity, C9ORF72 haploinsufficiency and TDP-43 accumulation and possibly in the development of in vivo diagnostic tests.
